Multicentric standardization of minimal/measurable residual disease in B‐cell precursor acute lymphoblastic leukaemia using next‐generation flow cytometry in a low/middle‐level income country

Ikoma, Maura Rosane Valério; Bertolucci, Camila M.; Conti‐Spilari, Joana E.; Oliveira, Elen; Simioni, Anderson João; Figueredo-Pontes, Lorena L; Furtado, Felipe Magalhães; Alegretti, Ana Paula; Azambuja, Ana Paula de; Gevert, Fabiola; Gomes, Bernadete Evangelho; Vitelli-Avelar, D. M.; Soares, Ana Cláudia C. V.; Ramos, Priscila M.; Santos, Berta; Cortez, Maria L.; Beltrame, Míriam Perlingeiro; Bacal, Nydia Strachman; Wagner, Alfred; Lucena‐Silva, Norma; Sandes, Alex Freire; Cunha, Fernanda Marques da; Oliveira, Gustavo H. M.; Costa, Edja Maria Melo de Brito; Yamamoto, Masahiro

doi:10.1111/bjh.18499

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In LMICs, strategies for enhancing flow cytometry laboratories and optimizing sensitivity must be prioritized. Efforts have been made in LMICs to standardize cost-effective panels for assessing MRD in ALL [69][70][71]. We recommend that MRD assessment be performed on bone marrow samples collected after each intensive cycle or, at the very least, every 3 months [17,72].…”

Section: Mrd Monitoring In Ph+ Allmentioning

confidence: 99%

How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings

Silva,

Rego

2023

Cancers

View full text Add to dashboard Cite

Recent studies have indicated that more than half of adult patients newly diagnosed with Ph+ ALL can now achieve a cure. However, determining the most suitable protocol for less-resourced settings can be challenging. In these situations, we must consider the potential for treatment toxicity and limited access to newer agents and alloSCT facilities. Currently, it is advisable to use less intensive induction regimens for Ph+ ALL. These regimens can achieve high rates of complete remission while causing fewer induction deaths. For consolidation therapy, chemotherapy should remain relatively intensive, with careful monitoring of the BCR-ABL1 molecular transcript and minimal residual disease. AlloSCT may be considered, especially for patients who do not achieve complete molecular remission or have high-risk genetic abnormalities, such as IKZF1-plus. If there is a loss of molecular response, it is essential to screen patients for ABL mutations and, ideally, change the TKI therapy. The T315I mutation is the most common mechanism for disease resistance, being targetable to ponatinib. Blinatumomab, a bispecific antibody, has shown significant synergy with TKIs in treating this disease. It serves as an excellent salvage therapy, aside from achieving outstanding results when incorporated into the frontline.

show abstract

Section: Mrd Monitoring In Ph+ Allmentioning

confidence: 99%

How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings

Silva,

Rego

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In their paper, Ikoma‐Colturato and colleagues 1 share their experiences in multicentric standardization of a sensitive multiparametric flow cytometry (MFC)‐based MRD assay in patients of B‐cell precursor ALL (B‐ALL) across laboratories in Brazil. MFC‐based B‐ALL MRD (MFC‐BMRD) assays have become popular due to their broad applicability and quick results as compared to molecular techniques.…”

Section: Figurementioning

confidence: 99%

United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward

Chatterjee

Patkar

2022

Br J Haematol

View full text Add to dashboard Cite

Assessment of measurable residual disease (MRD) using multiparameter flow cytometry in precursor B-cell acute lymphoblastic leukaemia (ALL) is routine. However, studies on the harmonization of laboratory techniques as well as on the interpretation of results are limited. Here, Ikoma-Colturato and colleagues from Brazil demonstrate multicentric standardization of B-ALL MRD using EuroFlow protocols. Commentary on: Ikoma-Colturato et al., Multicentric standardization of minimal/ measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.

show abstract

Multicentric standardization of minimal/measurable residual disease in B‐cell precursor acute lymphoblastic leukaemia using next‐generation flow cytometry in a low/middle‐level income country

Cited by 2 publications

References 12 publications

How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings

How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings

United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward

Contact Info

Product

Resources

About